Rare Pediatric Disease Designation Requests Skyrocket Ahead Of Voucher Program’s Sunset
Executive Summary
US FDA received 110 designation requests in July, a high mark that reflects the 60 days needed to review such requests ahead of the 30 September statutory expiration; agency is allowing email submission of RPD and orphan drug designation requests during the COVID-19 pandemic and expects to roll out an online portal for orphan designation requests later this year.
You may also be interested in...
US FDA Seeking New Orphan Products Office Director Amid Internal Moves
OOPD’s deputy director has been named the acting head of the office responsible for orphan and rare pediatric disease designations.
Drug Costs Not A Primary Driver Of Rare Disease Economic Burden
EveryLife Foundation study finds inpatient and outpatient care, not prescription drugs, are the primary excess medical costs associated with rare diseases.
Breakthroughs, Orphans Hit High Notes As US FDA’s 2020 Novel Approvals Play A Familiar Tune
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.